A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer
Authors:
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 41 (3) , 412-425
Abstract
No abstract availableKeywords
Funding Information
- GP-Pharm S.A., Spain
This publication has 26 references indexed in Scilit:
- Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate CancerDrugs, 2013
- Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developmentsBritish Journal of Cancer, 2011
- Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter studyClinical Therapeutics, 2010
- Understanding survival analysis: Kaplan-Meier estimateInternational Journal of Ayurveda Research, 2010
- LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussionCurrent Medical Research and Opinion, 2007
- How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?European Urology Supplements, 2005
- Androgen Deprivation Therapy for Prostate CancerJAMA, 2005
- LHRH analogues as anticancer agents: pituitary and extrapituitary sites of actionExpert Opinion on Investigational Drugs, 2001
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- Efficacy and Safety of Leuprorelin Acetate Depot for Prostate CancerUrologia Internationalis, 1996